PURPOSE: To investigate the cytostatic effect of 5-fluorouracil (5-FU) encapsulated in polyethylene glycol (PEG) liposomes with or without degradable starch microspheres (DSM) in a long-term trial using a rat liver tumor model. MATERIALS AND METHODS: The cytostatics were applied once either as a hepatic arterial infusion (HAI) or were systemically infused via the tail vein. Seven groups were compared with respect to tumor growth and survival times: 5-FU HAI (group I), 5-FU + DSM HAI (group II), PEG-5-FU HAI (group III), PEG-5-FU + DSM HAI (group IV), NaCl HAI (group V), 5-FU i.v. (group VI), and PEG-5-FU i.v. (group VII). RESULTS: Seven and 14 days after treatment in groups III and IV, only group IV had significantly inhibited tumor growth on day 21 compared to the groups treated intravenously. On day 28, none of the animals from the intravenously treated groups were still alive compared to a significantly longer survival time of 6 and 8 weeks in groups III and IV. CONCLUSION: Locoregional therapy with 5-fluorouracil encapsulated in PEGylated liposomes may further improve the treatment success with longer-lasting tumor regression and prolonged survival times.
PURPOSE: To investigate the cytostatic effect of 5-fluorouracil (5-FU) encapsulated in polyethylene glycol (PEG) liposomes with or without degradable starch microspheres (DSM) in a long-term trial using a ratliver tumor model. MATERIALS AND METHODS: The cytostatics were applied once either as a hepatic arterial infusion (HAI) or were systemically infused via the tail vein. Seven groups were compared with respect to tumor growth and survival times: 5-FU HAI (group I), 5-FU + DSM HAI (group II), PEG-5-FU HAI (group III), PEG-5-FU + DSM HAI (group IV), NaCl HAI (group V), 5-FU i.v. (group VI), and PEG-5-FU i.v. (group VII). RESULTS: Seven and 14 days after treatment in groups III and IV, only group IV had significantly inhibited tumor growth on day 21 compared to the groups treated intravenously. On day 28, none of the animals from the intravenously treated groups were still alive compared to a significantly longer survival time of 6 and 8 weeks in groups III and IV. CONCLUSION: Locoregional therapy with 5-fluorouracil encapsulated in PEGylated liposomes may further improve the treatment success with longer-lasting tumor regression and prolonged survival times.
Authors: Senat Krasnici; Alexander Werner; Martin E Eichhorn; Marcus Schmitt-Sody; Sascha A Pahernik; Birgitta Sauer; Brita Schulze; Michael Teifel; Uwe Michaelis; Kurt Naujoks; Marc Dellian Journal: Int J Cancer Date: 2003-07-01 Impact factor: 7.396
Authors: Jens Sperling; Christian Ziemann; Anika Gittler; Anna Benz-Weißer; Michael D Menger; Otto Kollmar Journal: Clin Exp Metastasis Date: 2015-02-19 Impact factor: 5.150
Authors: Minhyung Kim; Daniel T Fisher; Colin A Powers; Emmanuel M Gabriel; Alexis M Korman; Sandra Sexton; Andrei V Gudkov; Joseph J Skitzki Journal: J Surg Res Date: 2017-06-21 Impact factor: 2.192
Authors: Minhyung Kim; Colin A Powers; Leslie I Curtin; Daniel T Fisher; Sandra Sexton; Katerina V Gurova; Joseph J Skitzki; Renuka V Iyer Journal: J Surg Res Date: 2020-03-03 Impact factor: 2.192
Authors: Jens Sperling; Thilo Schäfer; Anna Benz-Weißer; Christian Ziemann; Claudia Scheuer; Otto Kollmar; Martin K Schilling; Michael D Menger Journal: Int J Colorectal Dis Date: 2012-12-15 Impact factor: 2.571